Abstract
Preclinical and initial clinical experiences with the direct oral thrombin inhibitor ximelagatran demonstrated both a short and long-term potential utility for this agent in the prevention and treatment of various thromboembolic disorders associated with both arterial and venous thrombosis. Oral administration of ximelagatran after surgery and continued for at least 6–12 d appears to be safe and effective as prophylaxis against venous thromboembolism after total knee replacement surgery. This was accomplished without laboratory monitoring of the intensity of ximelagatran anticoagulation or adjustment of the ximelagatran dose. Of the four postoperative oral ximelagatran dose regimens tested, the most effective is the 24 mg twice-daily; this regimen appears to provide at least comparable efficacy and safety as compared to postoperative low molecular weight heparin (LMWH) prophylaxis. Further testing of ximelagatran in phase III clinical trials in patients with various thromboembolic disorders is in progress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Weitz, J. I. (1997) Low-molecular-weight heparin. N. Engl. J. Med. 337.688–698. This review highlights the different mechanisms involved in the inhibiting hyper-coagulation states using either indirect or direct means.
Mousa, S. A. and Fareed, J. W. (2001) Advances in anticoagulant, antithrombotic, and thrombolytic drugs. Exp. Opin. Invest. Drugs 10(1), 157–162.
Hauptmann, J. and Sturzebecher, J. (1999) Synthetic inhibitors of thrombin and factor Xa: from the bench to the bedside. Thromb. Res. 93, 203–241.
Prasa, D., Svendsen, L., and Sturzebecher, J. (1997) The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb. Haemostasis 77, 498–503.
Eichinger, S., Wolzt, M., Schneider, B., et al. (1995) Effects of recombinant hirudin on coagulation and platelet activation in vivo: comparison with unfrac-tionated heparin and a LMWH preparation (Fragmin). Arterioscler. Thromb. Vase. Biol. 15, 886–892.
Kyrle, P. A., Westwick, J., Scully, M. F., et al. (1987) Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man—Effect of low dose aspirin. Thromb. Haemostasis 57,62–66.
Weiss, H. J. and Lages, B. (1988) Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 71, 629–635. Another documentation for the role of tissue factor as a defensive mechanism in wounds.
Wilcox, J. N., Smith, K. M., Schwartz, S. M., et al. (1989) Localization of tissue factor in normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 86, 2839–2843.
Toschi, V., Gallo, R., Lettino, M., et al. (1997) Tissue factor modulates throm-bogenicity of human atherosclerotic plaques. Circulation 95, 594–599.
Badimon, J. J., Lettino, M., Toschi, V., et al. (1999) Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow. Circulation 99, 1780–1787.
Tremoli, E., Camera, M., Tosch, V., et al. (1999) Tissue factor in atherosclerosis. Atherosclerosis 144, 273–278.
Von dem Borne, P. A., Koppelman, S. J., Bouma, B. N., et al. (1994) Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb. Haemostasis 72, 397–402.
Gustafsson, D., Antonsson, T., Bylund, R., et al. (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemostasis 79, 110–118. A comprehensive report on the influence of direct thrombin inhibitor on thrombin and the fibrinolytic system.
Eriksson, U. G., Johansson, L., Frison, L., et al. (1999) Single and repeated oral dosing of H 376/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood 94 (10 Suppl.), 26a.
Gustafsson, D., Nystrom, J.-E., Calsson, S., et al. (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171–181.
Sarich, T. C., Eriksson, U. G., Mattsson, C., et al. (2002) Inhibition of thrombin generation by the oral direct thrombin inhibitor Ximelagatran in shed blood from healthy male subjects. Thromb. Haemostasis 87, 300–305. This pharmacodynamic study demonstrated the effects of oral Ximelagatran on various markers of thrombin generation.
Petersen, P., on behalf of the SPORTIF II investigators. (2001) A long-term follow-up of Ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Blood 98(11), 706a, 2953.
Olsson, B. B. and Petersen, P. (2001) Fixed-dose oral direct thrombin inhibitor ximelagatran as an alternative for dose-adjusted warfarin in patients with non-valvular atrial fibrillation. Eur. Heart J. 22, 330, P1761.
Francis, C. W., Davidson, B. L., Berkowitz, S. D., et al. (2001) A randomized, double-blind, comparative study Ximelagatran (formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA). Thromb. Haemostasis (Suppl), July, OC44.
Colwell, W., Berkowitz, S. D., Davidson, B. L., et al. (2001) Randomized, double-blind, comparison of Ximelagatran, an oral direct thrombin inhibitor, and enoxa-parin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA). Blood 98(11), 706a, 2952.
Eriksson, B. I., Lindbratt, I. S., Kaleboi, P., et al. (2000) Methro II: Dose-Response Study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or total knee replacement. Haemostasis 30 (Suppl. 1), 20–21, 38.
Berntsson, P., Mattsson, C., Johansson, T., et al. (2001) Enhancement of fibrinolysis by melagatran via inhibition of thrombin-induced activation of PRO-CUP (TAFI). Thromb. Haemostasis (Suppl.), July, P2014.
Klement, P., Carlsson, S., Liao, P., et al. (2001) Melagatran, a safe alternative to hirudin in prevention of arterial thrombosis. Thromb. Haemostasis (Suppl.), July, P3078.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Mousa, S.A. (2004). Oral Thrombin Inhibitor Ximelagatran. In: Mousa, S.A. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods In Molecular Medicine™, vol 93. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-658-4:247
Download citation
DOI: https://doi.org/10.1385/1-59259-658-4:247
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-1-58829-083-0
Online ISBN: 978-1-59259-658-4
eBook Packages: Springer Protocols